Kolkata : Deepak Parekh-backed multi-specialty healthcare provider, Nephro Care India Limited (NCIL) has posted a standalone net profit of Rs 2.19 crore for the first half ended September 30, 2024. The company got listed on SME platform on NSE Emerge in July this year thus half yearly figures for the half year ended September 30, 2023 are not provided.
However, it registered 85.94% surge in standalone net profit at Rs 4.41 crore for the year ended March 31, 2024, as against Rs 2.37 crore in FY 22-23.
Revenue from operations on a standalone basis stood at Rs 17.69 crore for the half year ended September 30, 2024. For the year ended March 31, 2024, the company’s standalone revenue from operations grew by 59.31 % at Rs 27.23 crore, up from Rs 17.09 crore last year.
The company’s operating profit EBITDA stood at Rs 3.51 crore while the EBITDA margin was at 19.35 per cent for the half year ended September 30, 2024. NCIL expects its profitability to improve further as its mutispeciality hospital Vivacity achieves operational profit.
Commenting on the company’s performance during the period, Dr Pratim Sengupta, MD & CEO, Nephro Care India, said, “Our revenues from the existing renal care units has witnessed a significant surge. However, we recently opened two new renal care clinics and it typically takes about six months to break even. We also recently inaugurated our multispeciality hospital – Vivacity – entailing an investment of around Rs 36.51 crore. But despite that we have reported a net profit of Rs 2.19 crore in the first half of this financial year. We expect our profitability to improve significantly moving forward as our newly established units and the multispeciality hospital achieve operational profit over the next few quarters.”
Nephro Care, which currently has four comprehensive renal care units in West Bengal, is set to open two more units – at Shyambazar in Kolkata and Balasore in Odisha by the end of this financial year. “Work at the Shyambazar and Balasore units is progressing at a rapid pace and we hope to commence operations very soon,” Dr Sengupta said.
Bridging the demand-supply gap
Nearly 15 per cent of the country’s population suffers from high blood sugar levels and nearly 22 per cent from hypertension or high blood pressure and both these conditions pose a significant risk for developing renal diseases. However, the country lacks adequate infrastructure thereby limiting access to specialized renal care contributing to the high burden of end-stage kidney disease.
Government estimates suggest, nearly 2,20,000 patients develop ESRD (end stage renal disease) in India, leading to an additional annual dialysis demand of 34 million treatment sessions. However,
India presently has nearly 5,000 existing dialysis centres (including 1353 centres under PMNDP). This capacity will not be sufficient to meet the upcoming demand as the disease has been gaining traction due to various sociological, lifestyle and environmental factors, Dr Sengupta said, highlighting the need for setting up more such comprehensive renal care centres across the country.
NCIL, which currently has four renal care clinics in West Bengal, plans to set up 22 more such clinics across the country on a hub and spoke model by March 2026. The company has a vision of reaching out and impacting lives of close to one million patients suffering from chronic kidney disease by
setting up 300 such centres across the country in the next 10-15 years.
The company’s 100- bedded multispecialty hospital Vivacity Multispecialty Hospital at Madhyamgram in Kolkata, West Bengal, has already commenced operations, and will offer treatment services in various disciplines such as cardiology, medical oncology, gastroenterology, gynaecology and many others, including an advanced renal transplant unit in East India.
Vivacity also proposes to offer advanced dialysis facilities from its 30-bedded dialysis centre.
